Aim The efficacy and safety of bivalirudin when used concurrently with glycoprotein IIb/IIIa
inhibitors (GPI) is uncertain. In this systematic review and meta-analysis, we aimed to …

Aims To evaluate the impact of bivalirudin versus heparin on efficacy and safety outcomes of
ST-segment elevation myocardial infarction (STEMI) patients undergoing primary …

This study sought to investigate the relative safety and efficacy of bivalirudin versus heparin
plus glycoprotein (GP) IIb/IIIa inhibitors in patients undergoing percutaneous coronary …

Background Bivalirudin has been shown to be associated with less major bleeding than
heparin in patients undergoing percutaneous coronary intervention (PCI); but the …

Conflicting results comparing bivalirudin versus heparin anticoagulation in patients with ST-
segment elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Introduction The beneficial effects of bivalirudin during primary PCIs are controversially
discussed, data on unselected patients are rare. It was the aim of the study to compare …

Aims The present meta-analysis focused on investigating whether bivalirudin plus post-PCI
infusion was safer and more effective than heparin monotherapy in patients who developed …

Objectives: The aim of this meta-analysis was to compare the 30-day safety and efficacy of
bivalirudin with those of heparin with or without routine administration of a glycoprotein …

A variety of antithrombotic drugs are used during percutaneous coronary interventions
(PCIs). We aimed to investigate the practicability of the use of bivalirudin and GPIs in …

Abstract Background: In the HORIZONS-AMI (Harmonizing Outcomes with
RevasculariZatiON and Stents in Acute Myocardial Infarction) trial, 3,602 patients …